Erythropoietin-producing hepatocellular A2 (EphA2) is a member of the Eph tyrosine kinase receptor family that has been linked to various biological processes. In tumors, EphA2 overexpression is associated with noncanonical pathway activation, tumor progression, and a poor prognosis, which has emphasized its importance as a marker of malignancy. Studies on numerous cancer models have highlighted EphA2’s dual and often contradictory action, which can be attributed to EphA2′s interactions involving multiple pathways and different ligands, as well as the heterogeneity of the tumor microenvironment. In this review, we summarize the main mechanisms underlying EphA2 dysregulation in cancer, highlighting its molecular complexity. Then, we analyze therapies that have been developed over time to counteract its action. We discuss the limitations of the described approaches, emphasizing the fact that the goal of new options is high specificity without losing therapeutic efficacy. For this reason, immunotherapy or the emerging field of targeted protein degradation with proteolysis-targeting chimeras (PROTACs) may represent a promising solution that can be developed based on a deeper understanding of the molecular mechanisms sustaining EphA2 oncogenic activity.
Capicua-double homeobox 4 (CIC-DUX4)–rearranged sarcomas (CDS) are extremely rare, highly aggressive primary sarcomas that represent a major therapeutic challenge. Patients are treated according to Ewing sarcoma protocols, but CDS-specific therapies are strongly needed. In this study, RNA sequencing was performed on patient samples to identify a selective signature that differentiates CDS from Ewing sarcoma and other fusion-driven sarcomas. This signature was used to validate the representativeness of newly generated CDS experimental models—patient-derived xenografts (PDX) and PDX-derived cell lines—and to identify specific therapeutic vulnerabilities. Annotation analysis of differentially expressed genes and molecular gene validation highlighted an HMGA2/IGF2BP/IGF2/IGF1R/AKT/mTOR axis that characterizes CDS and renders the tumors particularly sensitive to combined treatments with trabectedin and PI3K/mTOR inhibitors. Trabectedin inhibited IGF2BP/IGF2/IGF1R activity, but dual inhibition of the PI3K and mTOR pathways was required to completely dampen downstream signaling mediators. Proof-of-principle efficacy for the combination of the dual AKT/mTOR inhibitor NVP-BEZ235 (dactolisib) with trabectedin was obtained in vitro and in vivo using CDS PDX-derived cell lines, demonstrating a strong inhibition of local tumor growth and multiorgan metastasis. Overall, the development of representative experimental models (PDXs and PDX-derived cell lines) has helped to identify the unique sensitivity of the CDS to AKT/mTOR inhibitors and trabectedin, revealing a mechanism-based therapeutic strategy to fight this lethal cancer. Significance: This study identifies altered HMGA2/IGF2BP/IGF2 signaling in CIC-DUX4 sarcomas and provides proof of principle for combination therapy with trabectedin and AKT/mTOR dual inhibitors to specifically combat the disease.
Capicua transcriptional repressor (CIC)-rearranged sarcoma, belonging to the undifferentiated round cells sarcoma family, is characterized by high metastatic rate and poor chemo response. CIC sarcoma represents a new entity harboring the recurrent chromosomal translocation between CIC and, in most of the cases, DUX4. CIC-DUX4 imposes a CIC-specific transcriptional signature, which drives cell transformation, proliferation, and migration. While the discovery of the fusion represented the first evidence of a role of CIC in cancer, a complete comprehension of CIC-rearranged activity is still required before providing new potential avenues for therapy. To date, a specific and effective treatment for CIC sarcoma has yet to be defined. In this review, we initially highlight the clinical features and pathogenesis of CIC-rearranged sarcomas along with current therapeutic approaches and then focus on the specific oncogenic mechanisms driven by the CIC-rearrangement. We discuss novel therapeutic options evoked by the aberrant relations of CIC-DUX4 with the IGF system, DUSP6, P300/CBP, and CCNE1. We also discuss how different mutations involving CIC might converge on a common upregulation of CIC-target genes across human cancers. A deeper understanding of the oncogenic mechanisms driven by the chimera CIC-DUX4 might provide novel therapeutic opportunities with a general impact in cancer.
Trabectedin impairs the HMGA2/IGF2BP2–3/IGF network and inhibits AKT pathway activity in combination with NVP-BEZ235 treatment. A and B, qRT-PCR analysis of HMGA2/IGF2BP2–3 mRNA expression (A) and Western blot analysis of HMGA2/IGF2BP2–3/IGF2/IGF1R protein expression (B) in PDX-CDS#4-C and PDX-CDS#3-C cells treated with 3 nmol/L trabectedin for the indicated time. At least three independent biological replicates were performed. One representative immunoblot is shown. For qRT-PCR, the data represent the mean ± SE. *, P < 0.05; **, P < 0.01; ****, P < 0.0001, one-way ANOVA. Each dot represents an independent experiment. GAPDH was used as a reference gene. C, Western blot analysis showing activation of IGF1R and the downstream mediator AKT in PDX-CDS#4-C and PDX-CDS#3-C cells treated with 3 nmol/L trabectedin for 24 hours with or without a subsequent 24 hours treatment with different doses of NVP-BEZ235. Three independent biological replicates were performed. One representative immunoblot is shown. GAPDH was employed for normalization purposes.
GSEAs and qRT-PCR validation reveal a unique transcriptional profile of CDS characterized by enriched expression of a HGMAs/IGF2BPs/IGF2 axis. A, GSEA reveals a significant enrichment of genes upregulated in patients with CDS versus Ewing sarcoma. CDS displayed a signature enriched for genes involved in embryonic stem cell development (Benporath_ES_1), KRAS signaling (Sweet_KRAS_TARGETS_DN), WT1 target genes (Kim_WT1_TARGETS_UP), and chromatin modification (Mikkelsen_NPC_HCP_WITH_H3K27ME3). The enrichment score curve was obtained using GSEA software. In the enrichment plot, the x-axis shows the rank order of genes from the most upregulated to the most downregulated between CDS and Ewing sarcoma samples. The vertical black line indicates the position of the enriched genes (Hit) comprising the gene set. The graph on the bottom shows the ranked list metric (signal-to-noise ratio) for each gene as a function of the rank in the ordered dataset. The heatmaps show the genes that contribute most to the enriched pathway or biological process resulting from the leading edge analysis. B, Validation of the RNA-seq results was performed by qRT-PCR and the results are shown in scatter plots. Each dot represents a tumor sample. Differential expression of genes between CDS and Ewing sarcoma was established by Student t test and correction for multiple comparisons using the Holm-Sidak method: **, P < 0.01; ****, P < 0.0001; ns, nonsignificant. The mean ± SE of relative mRNA expression (2–ΔΔCt) is reported as log2. GAPDH was used as a reference gene. C, Left, CIC-DUX4 silencing in PDX-CDS#4 cells by RT-PCR. Agarose gel electrophoresis image of a 233-base fusion transcript is shown. Right, relative mRNA expression (2−ΔΔCt) of HMGA2, IGF2BP2, IGF2BP3, and IGF2 after cell exposure to siCIC or scrambled (SCR) control siRNAs (40 nmol, 72 hours) by qRT-PCR. The mean ± SE of relative mRNA expression (2−ΔΔCt) is reported as log2. GAPDH was used as a reference gene. *, P < 0.05; **, P < 0.01; one-way ANOVA with respect to the control.